Market Performance - The North Exchange 50 Index saw a weekly increase of +0.58% from February 9 to February 13, 2026[3] - The average daily trading volume on the North Exchange was approximately CNY 18.575 billion, with a total trading volume of CNY 92.876 billion and a turnover rate of 16.85% during the same period[4][5] - The overall price-to-earnings (P/E) ratio for the North Exchange was approximately 46.94 times, which is higher than the ChiNext's 45.74 times but lower than the Sci-Tech Innovation Board's 78.61 times[21] Sector Performance - Among the 294 listed companies on the North Exchange, 103 companies had positive weekly growth, with the highest being Aide Technology (+144.72%) and Haiseng Medical (+133.86%)[10] - The media sector experienced a significant increase of +22.6%, while the oil and petrochemical sector saw a decline of -8.7%[10] Financing and Regulatory Measures - The North Exchange introduced a comprehensive package of measures to optimize refinancing, focusing on supporting quality listed companies and innovative small and medium-sized enterprises[40] - Key measures include improving the review process for quality companies, enhancing inclusivity for innovative SMEs, simplifying disclosure requirements, and strengthening regulatory oversight[41] Investment Strategy - The recommended investment strategy for 2026 emphasizes focusing on new productive forces in sectors such as renewable energy, intelligent manufacturing, and emerging consumption industries[27] - A bottom-up approach based on financial metrics is advised, targeting companies with high growth potential and strong R&D investment[27] Risk Factors - Potential risks include lower-than-expected policy support, rapid technological changes, and intensified market competition[3]

Core Insights - The A-share market has welcomed 16 new listings since 2026, with four medical device companies standing out as a highlight of the new year [1] - The newly listed medical device companies have shown impressive first-day performance, with all four stocks rising over 170% on their debut [1][3] - The strong stock performance is supported by positive earnings forecasts, with all four companies expected to report growth in 2025 [1][5] Group 1: Market Performance - The four medical device stocks, including Beixin Life, Haiseng Medical, Aide Technology, and Aishalen, experienced significant first-day gains, with Beixin Life rising by 183.33% on its debut [3] - As of February 13, the stock prices for these companies ranged from 18.77 yuan to 39.48 yuan, with total market capitalizations between 22.17 billion and 164.6 billion yuan [3] - The medical device sector is currently in a high-growth cycle, attracting significant capital market attention [7] Group 2: Company Performance and Projections - Beixin Life, which focuses on cardiovascular disease diagnostic devices, is projected to turn a profit in 2025, with expected revenues between 520 million and 560 million yuan, representing a growth of 64.24% to 76.88% [6] - Haiseng Medical anticipates a revenue of 345 million yuan in 2025, a year-on-year increase of 13.68%, while Aide Technology expects approximately 302 million yuan, up 9.74% [6] - Aishalen forecasts revenues between 890 million and 940 million yuan, with a growth rate of 28.65% to 35.89% due to increased demand and expanded production capacity [6] Group 3: Industry Trends and Future Prospects - The medical device IPO trend continues, with several companies, including Guangdong Boma Medical Technology, in the pipeline for listing [8] - Companies like Core Medical and Tongxin Medical are also vying to become the first domestic artificial heart stock, despite not yet being profitable [9] - The medical device sector is shifting from "concept speculation" to "performance-driven" investments, emphasizing the importance of technological originality and profitability [9]

Core Viewpoint - Haisheng Medical (920166.BJ) experienced a significant drop in stock price, closing at 29.56 yuan, a decrease of 14.29% after its listing on the Beijing Stock Exchange on February 12 [1] Group 1: Company Overview - Haisheng Medical issued up to 11,294,118 shares to unspecified qualified investors at a price of 12.64 yuan per share, ensuring that public shareholders hold at least 25% post-issue [1] - The total amount raised from the issuance was 142,757,651.52 yuan, with a net amount of 113,438,208.84 yuan after expenses, which is 25,698.72 million yuan less than originally planned [1] - The company plans to use the raised funds for upgrading and expanding its anesthetic monitoring and emergency medical device production, R&D testing center projects, and marketing service base construction [1] Group 2: Financial Details - The total issuance costs amounted to 2,931.94 million yuan, including 500.00 million yuan for sponsorship fees and 900.00 million yuan for underwriting fees [1] - On February 12, the stock closed at 34.49 yuan, reflecting a substantial increase of 172.86% from its initial listing price [2]

Core Insights - The report highlights the performance of the Beijing Stock Exchange (BSE) on February 12, 2026, with the BSE 50 index closing at 1,533.17 points, reflecting a change of 0.50% [3] - The overall trading volume on the BSE was 19.263 billion yuan, with a total of 721 million shares traded, indicating a decrease compared to the previous week's average daily trading volume of 20.484 billion yuan [3] - The report notes that the BSE's overall valuation stands at a price-to-earnings (P/E) ratio of 47.22 times, which is higher than the P/E ratios of the ChiNext and STAR Market, at 46.32 times and 78.83 times respectively [3][10] Market Performance - On February 12, 2026, the BSE saw mixed performance across various sectors, with the pharmaceutical and biotechnology sector leading with a gain of 6.2%, while the oil and petrochemical sector experienced a decline of 6.8% [3] - Among the 294 listed companies on the BSE, 113 companies saw their stock prices rise, while 171 companies experienced declines, with Haisheng Medical leading the gains at 172.86% [3][7] Valuation Analysis - The average P/E ratio for the BSE-listed companies is reported at 47.22 times, with the highest sector valuation in non-ferrous metals at 123.5 times, followed by telecommunications at 93.5 times [3][10] - The report indicates a continuous trend of higher valuations for BSE companies compared to those listed on the ChiNext [10] Trading Activity - The trading activity on the BSE was characterized by a turnover rate of 2.80%, with notable trading volumes in companies such as Binhang Technology, which had a transaction volume of 1.549 billion yuan [3][6] - The report provides detailed data on the top gainers and losers, with Haisheng Medical and ST Yunchuang being highlighted for their significant price movements [7][8]

Core Viewpoint - Zhejiang Haisheng Medical Equipment Co., Ltd. (stock code: 920166.BJ) was listed on the Beijing Stock Exchange, closing at 34.49 yuan with a significant increase of 172.86% on the first day of trading, indicating strong market interest and investor confidence in the company’s growth potential [1]. Company Overview - Haisheng Medical is a global provider of anesthesia and monitoring medical devices, focusing on the research, production, and sales of these products, which are widely used in various clinical settings such as anesthesia, ICU, and emergency departments [1]. - The company is controlled by Huang Haisheng and Wu Xiaoye, who collectively hold 54.92% of the shares, establishing them as the actual controllers of the company [1]. Financial Information - The company raised a total of 142.76 million yuan in its public offering, with a net amount of 113.44 million yuan after expenses, which was 25.70 million yuan less than initially planned [3]. - The financial performance from 2022 to mid-2025 shows a steady increase in revenue, with figures of 26.77 million yuan, 30.59 million yuan, 30.37 million yuan, and 15.56 million yuan for the respective periods [5]. - Net profit attributable to the parent company for the same periods was 7.01 million yuan, 7.80 million yuan, 7.09 million yuan, and 3.55 million yuan, indicating a relatively stable profit margin [5]. Project Funding and Allocation - The funds raised will be allocated to three main projects: upgrading and expanding production of anesthesia and emergency medical devices (24.84 million yuan), establishing a research and testing center (17.67 million yuan), and building a marketing service base (5.76 million yuan) [4]. - The total estimated investment for these projects is 48.27 million yuan, with the planned use of raised funds amounting to 37.04 million yuan [4]. Market and Policy Considerations - The company is subject to industry policies such as volume-based procurement and the "two-invoice system," which may impact its operational stability and performance [2]. - The company is expected to address these policy impacts and outline its strategies in future disclosures [2].

Trading Activity - The average daily trading volume on the North Exchange decreased by 28.69% to 204.93 billion CNY, down from 287.38 billion CNY in the previous week[5] - The weekly turnover rate for the North Exchange was 19.15%, indicating a decline in trading activity compared to previous weeks[7] Index Performance - The North 50 Index experienced a slight decline of 0.70% during the week, reflecting significant volatility in the market[14] - Other indices such as the Sci-Tech 50 and the ChiNext Index saw declines of 5.76% and 3.28% respectively, indicating a broader market downturn[14] Sector Analysis - Most sectors on the North Exchange reported negative median returns, with the beauty and personal care sector leading with a median increase of 2.32%, while the oil and petrochemical sector had the largest decline at -8.42%[20] - The computer industry had the highest median price-to-earnings (P/E) ratio at 139.57 times, indicating high valuation compared to other sectors[20] New Listings and Market Activity - There were two new IPOs on the North Exchange during the week, but no new stocks were listed[40] - The overall trading scale of the New Third Board decreased, with the innovative layer and basic layer trading amounts dropping by 15.61% and 25.94% respectively[34] Risk Considerations - There is a noted risk of pullback in North Exchange stocks, particularly as trading volumes have shown signs of contraction, which could lead to further declines in the North 50 Index[42]

Core Viewpoint - Haisheng Medical (920166) has been listed on the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices, which are widely used in various clinical departments [1][2]. Company Overview - Haisheng Medical is a global provider of comprehensive products in the anesthesia and monitoring medical device sector, with its main business activities centered around the R&D, production, and sales of these medical devices [2]. - The company’s products are extensively applied in departments such as anesthesiology, ICU, and emergency medicine [2]. Shareholding Structure - Prior to the issuance, Huang Haisheng directly held 47.11% of the company's shares, making him the controlling shareholder. His spouse, Wu Xiaoye, holds a 20.60% stake in Lixin Investment, which indirectly controls 7.81% of the company’s shares [2]. - Together, Huang Haisheng and Wu Xiaoye control a total of 54.92% of the company's shares, confirming their status as the actual controllers of Haisheng Medical [2]. Fundraising Details - The total amount raised from this issuance is approximately 142.76 million yuan, with a net amount of about 113.44 million yuan [2]. - The raised funds are intended for upgrading and expanding production of anesthesia and monitoring emergency medical devices, establishing a R&D testing center, and building a marketing service base [2].

Group 1 - The core business of the company focuses on anesthesia and monitoring medical devices, catering to clinical needs in ICU and emergency departments [2] - The company has established a product matrix for anesthesia, monitoring, surgical, and nursing products, mastering 14 core technologies that support its product offerings [2] - The company's main products are widely used in thousands of tertiary hospitals across the country [2] Group 2 - The issuance price of the company's shares is set at 12.64 yuan [2] - The issuance price-to-earnings ratio is 13.99, indicating the valuation of the company in the industry [2] - The subscription rate for the shares is 0.02%, reflecting investor interest in the offering [2]

每经AI快讯，2月12日，今日无新股申购；有1只新股上市，为北交所的海圣医疗。 ...

Core Viewpoint - The company, Haiseng Medical, has successfully listed on the Beijing Stock Exchange, focusing on the research and manufacturing of anesthesia and monitoring medical consumables, establishing itself as a leading enterprise in this sector in China [1][3]. Company Overview - Haiseng Medical is recognized as a national-level specialized and innovative "little giant" enterprise, with a product matrix that includes anesthesia, monitoring, surgical, and nursing categories [1]. - The company has developed 14 core technologies that form a strong technical moat for its product matrix, including innovations in pressure sensors, signal acquisition, and various medical device manufacturing processes [6]. Financial Performance - The company reported significant revenue growth driven by its core technologies, with revenues from these products reaching 2.23 billion, 2.54 billion, 2.53 billion, and 1.32 billion from 2022 to the first half of 2025, accounting for over 83% of its main business income during these periods [6]. - The company has established stable relationships with major clients, achieving sales coverage across all 31 provinces, autonomous regions, and municipalities in China, as well as exporting to key international markets [6]. Market Position - Haiseng Medical is positioned as a leading enterprise in the anesthesia and monitoring medical consumables sector, with a competitive edge reflected in its product offerings and technological advancements [3][6]. - The company has a market capitalization of 1 billion yuan, with an issue price of 12.64 yuan per share [3]. Investment Direction - The company plans to allocate raised funds primarily towards upgrading and expanding production capacity for emergency medical devices (1.74 billion yuan, 46.95%), establishing a research and testing center (1.39 billion yuan, 37.52%), and building a marketing service base (0.58 billion yuan, 15.54%) [3]. Challenges - Haiseng Medical faces the risk of production capacity saturation, as its existing capacity is nearing full utilization. Without timely expansion, the company may struggle to meet the growing market demand, potentially hindering its future growth [7].